ArticleJournal of the National Cancer Institute2008
Antitumor efficacy testing in rodents.
Article in Journal of the National Cancer Institute, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- A high-throughputActa pharmaceutica Sinica. B · 2023Article
- ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.Cancer research · 2022Article
- Statistical analysis of longitudinal data on tumour growth in mice experiments.Scientific reports · 2020Article
- Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study.Cancers · 2019Article
- A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats.Pharmaceutical research · 2019Article
- Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX).PeerJ · 2019Article
- Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy.Clinical pharmacology : advances and applications · 2019Article
- Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.Molecular cancer therapeutics · 2018Article
- Article
- Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.Translational oncology · 2017Article
- Evaluation of Ceiba pentandra (L.) Gaertner bark extracts for in vitro cytotoxicity on cancer cells and in vivo antitumor activity in solid and liquid tumor models.Cytotechnology · 2016Article
- Metformin as a new anti-cancer drug in adrenocortical carcinoma.Oncotarget · 2016Article
- Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours.Scientific reports · 2016Article
- Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Quantitative volumetric imaging of normal, neoplastic and hyperplastic mouse prostate using ultrasound.BMC urology · 2015Article
- Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts.Korean journal of urology · 2015Article
- GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.Oncotarget · 2015Article
- Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.Nature reviews. Clinical oncology · 2015Review
- A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.Science translational medicine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, often guide the selection of agents for clinical development. If inappropriate or inaccurate recommendations are made on the basis of these preclinical studies, then additional costs are incurred. In this commentary, I discuss the issues associated with preclinical rodent efficacy studies. These include the identification of proper preclinical efficacy models, the selection of appropriate experimental endpoints, and the correct statistical evaluation of the resulting data. I also describe important experimental design considerations, such as selecting the drug vehicle, optimizing the therapeutic treatment plan, properly powering the experiment by defining appropriate numbers of replicates in each treatment arm, and proper randomization. Improved preclinical selection criteria can aid in reducing unnecessary human studies, thus reducing the overall costs of anticancer drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.